Company / CIK 0001651311
Merus N.V.
- Ticker
- MRUS
- Insiders on file
- 1
- Federal contracts on record
- none matched
- Lobbying filings on record
- none matched
- SEC filings
- EDGAR ↗
- Latest trade on record
- December 29, 2025
Merus N.V. (MRUS) has 1 insider on file who disclosed 11 transactions in the last 12 months (11 open-market buys, 0 sales, about $7.59B at reported prices). No federal contract award that started in the last 180 days was found for a recipient with exactly this name; no lobbying filing names it as client this year.
Merus N.V. in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
1 person accounts for the disclosed buying and selling in Merus N.V. over the last 12 months; the most active is GENMAB A/S with $7.6B.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| GENMAB A/S | Insider | 11 | 11 | 0 | December 30, 2025 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GENMAB A/S | MRUS | Buy P | December 29, 2025 | December 30, 2025 | 1d | 75,867,199 | $97 | $7.36B | indirect | Form 4 ↗ | |
| GENMAB A/S | MRUS | Buy P | December 29, 2025 | December 30, 2025 | 1d | 1,052,806 | $97 | $102.1M | indirect | Form 4 ↗ | |
| GENMAB A/S | MRUS | Buy P | December 26, 2025 | December 30, 2025 | 4d | 2,978 | $97 | $289K | indirect | Form 4 ↗ | |
| GENMAB A/S | MRUS | Buy P | December 26, 2025 | December 29, 2025 | 3d | 142,610 | $97 | $13.8M | indirect | Form 4 ↗ | |
| GENMAB A/S | MRUS | Buy P | December 24, 2025 | December 29, 2025 | 5d | 96,082 | $97 | $9.3M | lateindirect | Form 4 ↗ | |
| GENMAB A/S | MRUS | Buy P | December 23, 2025 | December 29, 2025 | 6d | 561,042 | $97 | $54.4M | lateindirect | Form 4 ↗ | |
| GENMAB A/S | MRUS | Buy P | December 22, 2025 | December 29, 2025 | 7d | 15,710 | $97 | $1.5M | lateindirect | Form 4 ↗ | |
| GENMAB A/S | MRUS | Buy P | December 19, 2025 | December 22, 2025 | 3d | 66,264 | $97 | $6.4M | indirect | Form 4 ↗ | |
| GENMAB A/S | MRUS | Buy P | December 18, 2025 | December 22, 2025 | 4d | 212,177 | $97 | $20.6M | indirect | Form 4 ↗ | |
| GENMAB A/S | MRUS | Buy P | December 17, 2025 | December 18, 2025 | 1d | 150,795 | $97 | $14.6M | indirect | Form 4 ↗ | |
| GENMAB A/S | MRUS | Buy P | December 16, 2025 | December 18, 2025 | 2d | 120,752 | $97 | $11.7M | indirect | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "Merus N.V.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
No LDA filing posted since October 2025 names "Merus N.V." as the client. Filings under a subsidiary or trade-association name are not matched — search lobbying.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 11 | December 18, 2025 | December 30, 2025 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.